Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
Condition: Intrahepatic Cholangiocarcinoma Interventions: Drug: Camrelizumab; Drug: Apatinib Sponsors: Sun Yat-sen University; Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials